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Background and Purpose The Early Stroke Trial (EST) is a randomized, double-blind, placebo-controlled trial to assess the effect of monosialoganglioside GM-1 in improving recovery in patients who experienced an ischemic supratentorial stroke.
Methods Sixteen clinical centers recruited 805 patients, of whom 792 were confirmed to be eligible. Treatment, consisting of a first dose of either 200 mg GM-1 or placebo, was initiated within 5 hours of the onset of stroke; a second dose of either 100 mg GM-1 or placebo was administered 12 hours later. Thereafter, patients received a daily injection of 100 mg GM-1 or placebo intravenously from day 2 through 10 and intramuscularly from day 11 through 21. Patients were followed up for a total of 4 months.
Results Survival was similar in the two treatment groups. Improvement in neurological status, as measured by the C urrent understanding of the events occurring during brain ischemia suggests that ischemic stroke is potentially treatable if medications restoring blood flow or preventing neuronal death are administered early. 1 - 2 The treatment of acute ischemia in myocardial infarction also emphasizes the importance of an early treatment; patients treated with intravenous streptokinase showed a consistent trend of increasing efficacy with decreasing time to initiation of treatment. 3 A similar trend was reported also for the treatment of acute ischemic stroke with the calcium antagonist nimodipine. 4 Gangliosides are a class of gh/cosphingolipids present in the mammalian nervous system and have been associated with nerve repair and regrowth. 3 A purified preparation of monosialoganglioside (GM-1) has been developed recently, with protective effects in acute cerebral ischemia that could be due, at least in part, to the attenuation of excitotoxicity. 6 The results of a few previous clinical trials suggest a therapeutic efficacy of GM-1 in acute ischemic stroke 7 -8 and subarachnoid hemorrhage. 9 We report here the results of a randomized, placebocontrolled, double-blind, multicenter study conducted to assess the efficacy and safety of GM-1 with a loading dose administered within 5 hours after the onset of an ischemic stroke of the cerebral hemispheres: the Early Stroke Trial (EST). The design, organization, and baseline results of the trial were described in detail elsewhere 10 and are only summarized here.
Subjects and Methods Patient Selection
All consecutive patients with a focal cerebral deficit of acute onset admitted at one of the 16 participating clinical centers at the time of the study were considered for inclusion. The preliminary diagnosis was based on a neurological evaluation and assessment of clinical course: a unilateral motor deficit of sudden onset, clinically attributable to an ischemic lesion of one cerebral hemisphere, was the main clinical criterion. A computed tomogram of the brain was required before randomization to rule out disease processes other than focal cerebral ischemia. Patients were potentially eligible if they could be enrolled within 5 hours of onset of stroke, were not stuporous or comatose, had persisting neurological motor deficit at the time of randomization, scored 8.5 or less on the Canadian Neurological Scale (CNS), 11 and had given informed consent. More detailed eligibility criteria have been published elsewhere.
10
Experimental Design, Treatment Regimens, and Blinding
Patients enrolled were treated according to the routine therapeutic management of each clinical center and randomized, with a double-blind design, to additional treatment with either GM-1 or placebo. To balance the GM-1 and placebo groups for known prognostic variables within each clinical center, patients were stratified by age (^65 versus >65 years), sex, and clinical severity (CNS score of 55 versus >5). 12 Patient groups were balanced for allocation to treatment or placebo within centers and strata using randomization schedules with blocks.
Study medication was supplied in glass ampules containing a 2-mL solution of either 100 mg GM-1 or placebo that were identical in appearance and packaging. The treatment regimen was 200 mg given as a first intravenous dose within 5 hours of the onset of stroke followed by a second intravenous dose of 100 mg 12 hours later; subsequently, patients received a daily intravenous dose of 100 mg from day 2 through 10 and an intramuscular dose of 100 mg from day 11 through 21. Patients who for any reason interrupted or discontinued study treatment after randomization were followed up in the same way as those who did not.
Baseline and Follow-up Assessments
The following baseline information was collected for each randomized patient: (1) demographic data; (2) results of physical, cardiovascular, and neurological examinations; (3) results of electrocardiography, hematologic tests, and urinaryses; (4) a computed tomogram of the brain without contrast medium; and (5) a CNS score.
Patients underwent follow-up examinations, including the CNS, daily for the first 15 days, at day 21, and at months 2 and 4.
Outcome Measures
The main outcome measures were mortality and the change in CNS score between baseline and the 4-month follow-up assessment among survivors. The CNS covers the following items of the neurological examination: level of consciousness; orientation; speech; and motor deficit of face, arm, and leg. The score ranges from 1.5 (worst) to 10 (best). We used a score of 0 for patients who became comatose during follow-up. If the score at 4-month follow-up was not known for a surviving patient, it was inferred using the last available score.
Statistical Methods
The sample size of 800 patients was calculated to have an 80% power to detect a true difference among survivors at 4 months in the two treatment groups of 0.5 points in the mean change in CNS score between baseline and the 4-month assessment, assuming a 5% one-sided a level. Allowing for a death rate of 25% within 4 months, the two treatment groups were expected to decrease to a total of 600 anaryzable patients.
The planned analysis compared survival in the 4 months after stroke in the GM-1 and placebo groups using KaplanMeier survival curves 12 and the log-rank test (two-tailed, a=.O5). 13 In the absence of a statistically significant difference in survival, the main analysis was to consider the change in CNS score between baseline and the 4-month follow-up assessments among survivors.
The change in neurological score in the GM-1 and placebo groups was compared using ANCOVA 14 and including the following variables in the model: treatment, center, stratum, CNS score at baseline, and age. According to study protocol, the test for primary analysis was one tailed (a=.O5). Efficacy analyses were conducted on eligible patients. An intention-totreat analysis was also performed on all randomized patients. Safety was assessed by comparing the rates and causes of death, adverse experiences, recurrence of stroke, and abnormal laboratory test results in the two groups of all randomized patients. All comparisons were made by Student's t test for continuous variables and Fisher's exact test for categorical variables (two-tailed, a=.10).
Organization
The EST organization included 16 clinical centers, a coordinating center, two data analysis centers, a Steering Committee, a Central Adjudication Committee, and an Advisory Review and Treatment Effect Monitoring Committee (ARTEMC). Fifteen of the clinical centers were located in Europe and one in the United States. The Steering Committee had overall responsibility for the study and addressed and resolved policy issues encountered during the course of the study. The Central Adjudication Committee reviewed and validated in a blinded fashion the eligibility of patients entered into the study and the outcome events or measures reported by the clinical investigators.
The treatment code was disclosed only after all decisions about the eligibility of patients, the causes of death, and the validity of outcome measures were made, and a computer tape of the final data was provided to the ARTEMC. The main analysis was conducted in collaboration with the two data analysis centers.
Results

Patient Enrollment
Of 8781 stroke patients admitted to the 16 clinical centers over the 3-year period between May 1987 and April 1990, 834 (9.5%) were eligible for EST. The primary reason for exclusion was a time interval between stroke onset and hospital admission of either over 5 hours (47.5%) or unknown duration (19.8%). Other common reasons for exclusion were either CNS score (29.9%) or age (21.8%) out of range.
Of the 834 eligible, 805 patients (96.5%) gave their informed consent and were randomized (401 placebo, 404 GM-1). Thirteen patients (5 treated with placebo and 8 with GM-1) were ruled ineligible by the Central Adjudication Committee because they were judged not to have the disease of interest, a classification ratified by the ARTEMC.
Patient Characteristics at Entry
Of the 792 truly eligible patients, 396 were in the placebo and 396 in the GM-1 group. The baseline demographic and clinical characteristics of these patients are summarized in Table 1 . The two groups were comparable for age, sex, smoking habits, alcohol abuse, cardiovascular history, cerebrovascular history, and CNS score at entry. The majority of subjects had substantial cardiovascular comorbidity. Only 22.7% of placebo patients and 22.2% of those treated with GM-1 had a history of transient ischemic attacks or reversible ischemic neurological deficits. The median time from stroke onset to randomization was 4.0 hours in both the placebo and GM-1 groups.
Adherence to Protocol
All possible efforts were made to obtain complete follow-up information on all patients randomized. For 5 patients, all randomized to placebo, no information was obtained about survival status at month 4; they were lost to follow-up after 2, 7, 14, 20, and 61 days, respectively. These 5 patients were censored at the time of loss to follow-up in the Kaplan-Meier survival curve calculation. The treatment code was broken by a local investigator during the course of the study for 3 patients; 2 patients were found to be taking placebo and 1 taking GM-1. The 2 patients taking placebo died on days 2 and 29, respectively. The patient on GM-1 experienced two episodes of hyperthermia, shivering, and confusional state leading to treatment discontinuation and later developed an acute polyradiculopathy. Table 2 summarizes the reasons for the early discontinuation of study medication. The rates of discontinuation for reasons other than death were quite comparable between treatment groups. Only 3 patients, all receiving GM-1, stopped study medication early because of an adverse experience. Table 3 summarizes the number of surviving patients for whom the CNS outcome was not assessed at 4 months. The rates were quite low for both treatment groups (placebo, 4.3%; GM-1, 2.0%).
Mortality
During the 4-month follow-up period, death from any cause occurred in 82 eligible patients receiving GM-1 and 77 patients receiving placebo. The Kaplan-Meier estimates of death rate were 20.7% in the GM-1 group and 19.5% in the placebo group, a difference not statistically significant by the log-rank test (P=.63). Two randomized but ineligible patients in each treatment arm died. An autopsy was performed in 41 patients (25.2%). Deaths were classified as vascular or nonvascular, and no significant differences were observed between treatment groups within each category (Table  4) . New strokes occurred in 34 patients, 14 in the placebo group and 20 in the GM-1 group. The frequency was not significantly different between the two groups (P=.3S). Three patients in the placebo group and 2 in the GM-1 group died because of a new fatal stroke.
Efficacy Analysis
The analysis of efficacy was based on the change in CNS score between baseline and 4-month assessments because there was no statistically significant difference in mortality between the treatment groups. This analysis included all 633 surviving eligible patients; 608 of them underwent the 4-month evaluation, and for 25 patients the change was calculated based on the last available examination. The most rapid improvement in neurological status occurred in the first days after randomization. The covariate-adjusted changes in score were 2.58 for GM-1 and 2.36 for placebo; this 0.22 difference favored GM-1 (/ > =.O6). The 95% confidence interval of the covariate-adjusted treatment effect is shown as the top bar in the Figure. An intention-to-treat analysis on change in CNS score at 4 months yielded a covariateadjusted treatment effect of 0.21 (P=.O7), similar to that based on truly eligible patients.
TABLE 4. Causes of Death Categorized by Treatment
Effect by Time to Treatment
Because of the postulated therapeutic mechanism of GM-1, a trend of increasing efficacy with earlier initiation of treatment was expected. We therefore analyzed the subgroups of patients treated within and after 4 hours (Figure) . The covariate-adjusted improvement for the 365 patients treated within 4 hours was 2.85 with GM-1 (n=171) and 2.44 with placebo (n=194), yielding a difference of 0.41 points (P=.O16, one-tailed). Consistently, the covariate-adjusted improvement for the 268 patients treated after 4 hours was 2.24 with GM-1 (n=143) and 2.26 with placebo (n = 125), yielding a difference of -0.02 point (^=.530, one-tailed).
Safety Analyses
The frequency of adverse experiences other than death was similar in the two groups (Table 5 ). Adverse experiences were sufficiently severe or prolonged to lead to early permanent discontinuation of study drug in 3 patients in the GM-1 group and no patients in the placebo-treated group. Table 5 shows the distribution of the five most common adverse events in the two treatment groups; for none of these events was the frequency significantly different between treatment groups. Rash and other skin reactions occurred in 8 patients in the GM-1 group and 2 in the placebo group. In only 2 GM-1-treated patients did the rash lead to early permanent discontinuation of treatment. One patient experienced severe allergic reactions. This was a 62-year-old man who developed a stroke while hospitalized for atrial fibrillation and suspected myocardial infarction. His medical history was positive for alcohol abuse, atrial fibrillation, congestive heart failure, angina, liver insufficiency, diabetes, and chronic symmetric sensory neuropathy. On days 5 and 7 after stroke, the patient had hyperthermia, shivering, and confusional state. At the second episode, the patient was transferred to an intensive care unit because of hemodynamic failure, the treatment code was broken, and the drug was discontinued. Three days later the patient experienced the onset of an acute progressive polyradiculopathy, consistent with GuillainBarr6 syndrome. At 4 months he was alive and had improved. A series of laboratory tests was compared in the two treatment groups including liver function, blood proteins, glycemia, renal function, blood electrolytes, blood lipids, blood cell counts, and prothrombin time. Our analyses did not show any clinically important difference between the two treatment groups; vital signs (blood pressure, pulse frequency, and body temperature) were similar over time in the two groups.
Discussion
Recent pathophysiologic studies have broadened our understanding of the biochemical events occurring in the hours immediately after an ischemic stroke.
1 Early therapy can be targeted to the zone of brain tissue suffering ischemic penumbra to prevent further neuronal death and to stop the progressive enlargement of irreversibly damaged tissue. Time is a crucial factor and determines the therapeutic window, out of which no benefit can be expected.
Two treatment approaches are possible either alone or in combination: protect the threatened brain tissue using cytoprotective drugs such as GM-1 or restore blood flow by removing the occlusion of the vascular supply with a fibrinorytic agent. 2 Theoretically, better results might be obtained by combining a cytoprotective drug administered as soon as possible after the onset of symptoms with a fibrinolytic drug given after the ischemic nature of the event has been determined.
A 5-hour time limit was adopted in the EST when it began in 1987 after it was demonstrated that a sizable number of stroke patients could be admitted to a hospital and evaluated within 4 to 5 hours from onset of stroke 15 despite the common practice of not referring subjects with stroke in the acute phase to a specialized hospital. 16 The trial recruited the planned number of patients over a 36-month period, the patients were evaluated thoroughly, and the number of patients lost to follow-up was very small (0.6%). Compliance with the medication regimen of the study was satisfactory. We assessed mortality and neurological status in surviving patients using the 1986 version of the CNS. This scale is short and easy to administer and was found to have satisfactory reliability. 1117 No statistically significant differences were found in mortality.
We found a difference in neurological recovery favoring GM-1. The magnitude of this difference in score change was 0.22 (F=.O6). It is difficult to translate this score change into a measure of clinical improvement because the CNS has not been validated in functional terms. The change in score between baseline and the 4-month assessment among placebo-treated patients was 2.36. However, it is relevant to underline that patients treated with GM-1, in the dose and treatment schedule used, experienced on average a 10% CNS improvement with respect to placebo-treated patients.
According to the suggested biological mechanism of GM-1 action in neuronal ischemia, we further explored this difference within or after 4 hours. The subgroup of patients treated within 4 hours showed a significant difference in favor of GM-1, whereas the subgroup of patients treated later experienced no difference. The results of this post hoc analysis were not due to imbalance in baseline characteristics, since the two subsamples were comparable for age, sex, and baseline severity and experienced mortality similar to the whole sample.
From a clinical point of view, and taking into account the limitations of the CNS in scoring a functional improvement, 18 these findings indicate that GM-1 is efficacious, especially if the treatment is introduced early, which is in line with data from a recent nimodipine trial. 4 The safety of GM-1 is supported by analyses involving mortality, adverse experiences, laboratory tests, and vital signs. GM-1 was not accompanied by clinically important adverse experiences and did not modify survival. Only one adverse event observed among patients receiving GM-1 deserves some discussion, which is the patient fully reported in "Results." This case was carefully examined by the Central Adjudication, Steering, and Safety Committees, and retained only a temporal relation between the administration of GM-1 and the development of polyradiculopathy. Whether the use of GM-1, or other exogenous gangliosides, increases the risk of developing a Guillain-Barr6 syndrome remains unknown. 19 A historic cohort study suggested that this risk, if any, should be minimal. 20 The results of the present trial are encouraging, particularly when compared with those from other large-scale trials on acute ischemic stroke, 421 because the dose and treatment schedule of GM-1 as used had, for all practical purposes, no toxicity while demonstrating a clinical improvement that was pronounced and statistically significant with very early treatment.
